SOX9 and hepatocellular carcinoma: Silencing of Sox9 in HCC cells (Huh7 and Hep3B) increased the number of cells in apoptotic phase compared with NTC when treated with doxorubicin or cisplatin, and sensitized HCC cells to these chemotherapeutic agents.